팝업레이어 알림
About Rznomics
Our vision is to treat/conquer various human intractable diseases such as hepatocellular carcinoma, intractable cancers, degenerative diseases and genetic diseases through development of innovative RNA-based biopharmaceutical.
About Rznomics
Excellence in Technology
-
Dual function in a single molecule
-
Modular Engineering
-
Disease-related RNA target specificity
-
High Performance
-
Continuous regulation of gene expression
Rznomics Pipeline
PIPELINE
Rznomics has core competencies to meet a variety of
unmet medical needs through development of
biopharmaceutical based on RNA platform
technology for cancer/intractable diseases.
NEWS & PRESS
Latest news about Rznomics or Stay informed about Rznomics
-
"Ultimately, Deep Science and Rational Evidence Win Over Inve...
Rznomics' Strategy for Investor Confidence Ahead of Special Technology-Based IPO"Rational evid...
-
Rznomics Secures KRW 20.3 Billion in Pre-IPO Funding, Bringing Tot...
RNA-based gene therapy developer Rznomics announced on the 23rd that it has successfully raised KRW...
-
Candidate for Rznomics Glioblastoma Treatment, Approved FDA Expand...
Candidate for Rznomics Glioblastoma Treatment, Approved FDA Expanded Access Program Available t...
- Head Office#327, Software & ICT Hall, 152, Jukjeon-ro, Suji-gu, Yongin, 16890, Korea
- TEL. 031-706-8730
- FAX. 031-8018-8734
- E_mailrznomics@rznomics.com
- Research Institute and Pangyo branch office#801(Pangyo branch office), #803(Research Institute) Innovalley Bldg. C, 253, Pangyo-ro, Bundang-gu, Seongnam, 13486, Korea
- TEL. 031-706-8730
Copyright(C) 2019 Rznomics. All Rights Reserved.
